Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dramatic clinical response to dabrafenib plus trametinib in anaplastic thyroid carcinoma and the challenges faced during the COVID-19 pandemic.

Archives of endocrinology and metabolism - 1 Nov 2021

Bueno Fernanda, Abelleira Erika, von Stecher Florencia, de Lima Andrea Paes, Pitoia Fabián

Abstract excerpt

Anaplastic thyroid carcinoma is the rarest tumor of the thyroid gland, representing less than 2% of clinically recognized thyroid cancers. Typically, it has an extremely rapid onset, fatal outcomes in most cases, and a median overall survival of 3 to 10 months despite aggressive multidisciplinary management. The presence of targetable mutations in anaplastic thyroid carcinoma patients is an opportunity for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Imidazoles
Share to Oximes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Pandemics

Share to Pyridones

Share to Pyrimidinones

Share to SARS-CoV-2

Share to Thyroid Carcinoma, Anaplastic

Share to Thyroid Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 33587835
DOI: 10.20945/2359-3997000000325
PMCID: PMC10065318

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dramatic clinical response to dabrafenib plus trametinib in anaplastic thyroid carcinoma and the challenges faced during the COVID-19 pandemic.PMID 33587835Read ↗

Advances in the management of anaplastic thyroid carcinoma: transforming a life-threatening condition into a potentially treatable disease.Semantic proximity Read ↗

Anaplastic thyroid cancer:Improved understanding of what remains a deadly disease.Semantic proximity Read ↗

Evaluating new treatments for anaplastic thyroid cancer.Semantic proximity Read ↗

Promising Therapeutic Targets for Recurrent/Metastatic Anaplastic Thyroid Cancer.Semantic proximity Read ↗

Mutational Landmarks in Anaplastic Thyroid Cancer: A Perspective of a New Treatment StrategySemantic proximity Read ↗

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.Semantic proximity Read ↗

Target therapy for BRAF mutated anaplastic thyroid cancer: a clinical and molecular study.Semantic proximity Read ↗

Recent advances in anaplastic thyroid cancer management.Semantic proximity Read ↗

Untitled literature recordSemantic proximity Read ↗

Clinical and Translational Challenges in Thyroid Cancer.Semantic proximity Read ↗

NOVEL INSIGHTS IN ADVANCED THYROID CARCINOMA: FROM MECHANISMS TO TREATMENTS: Molecular insights into the origin, biology, and treatment of anaplastic thyroid carcinoma.Semantic proximity Read ↗

Advances in targeted therapy for anaplastic thyroid carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.